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Repeated exposure to systemic inﬂammation and risk of new
depressive symptoms among older adults
JA Bell1, M Kivimäki1, ET Bullmore2, A Steptoe1, MRC ImmunoPsychiatry Consortium4 and LA Carvalho1,3
Evidence on systemic inﬂammation as a risk factor for future depression is inconsistent, possibly due to a lack of regard for
persistency of exposure. We examined whether being inﬂamed on multiple occasions increases risk of new depressive symptoms
using prospective data from a population-based sample of adults aged 50 years or older (the English Longitudinal Study of Ageing).
Participants with less than four of eight depressive symptoms in 2004/05 and 2008/09 based on the Eight-item Centre for
Epidemiologic Studies Depression scale were analysed. The number of occasions with C-reactive protein ⩾ 3 mg l− 1 over the same
initial assessments (1 vs 0 occasion, and 2 vs 0 occasions) was examined in relation to change in depressive symptoms between
2008/09 and 2012/13 and odds of developing depressive symptomology (having more than or equal to four of eight symptoms) in
2012/13. In multivariable-adjusted regression models (n= 2068), participants who were inﬂamed on 1 vs 0 occasion showed no
increase in depressive symptoms nor raised odds of developing depressive symptomology; those inﬂamed on 2 vs 0 occasions
showed a 0.10 (95% conﬁdence intervals (CIs) =− 0.07, 0.28) symptom increase and 1.60 (95% CI = 1.00, 2.55) times higher odds. In
further analyses, 2 vs 0 occasions of inﬂammation were associated with increased odds of developing depressive symptoms among
women (odds ratio (OR) = 2.75, 95% CI = 1.53, 4.95), but not among men (OR= 0.70, 95% CI = 0.29, 1.68); P-for-sex interaction = 0.035.
In this cohort study of older adults, repeated but not transient exposure to systemic inﬂammation was associated with increased
risk of future depressive symptoms among women; this subgroup ﬁnding requires conﬁrmation of validity.
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INTRODUCTION
Mental disorders contribute greatly to the global burden of
disease1 and depression is the largest driver of morbidity
associated with these disorders.2 A large body of evidence
supports immune dysfunction in the form of low-grade systemic
inﬂammation as a characteristic of depression, with meta-analyses
having established higher circulating levels of pro-inﬂammatory
factors C-reactive protein (CRP), interleukin-6 (IL-6) and tumour
necrosis factor alpha (TNF-α) among adults with than without
depressive disorders.3 Still unclear, however, is whether systemic
inﬂammation is a risk factor for future depression.
Plausible pathways exist for depressogenic effects of inﬂamma-
tion including disrupted metabolism of mood-enhancing neuro-
transmitters, creation of neurotoxic metabolites and chronically
heightened stress responses,4–6 but prospective population-based
ﬁndings are mixed7 with reports of both a positive link8–11 and of
no such link.12–14 One possible explanation for these mixed results
is the issue of inﬂammation chronicity. It is reasonable to expect
that pro-inﬂammatory signals need to persist over time in order to
induce depression; however, most studies conducted thus far
have measured inﬂammation only once and cannot capture these
potential effects. This leaves unanswered the question of whether
exposure to systemic inﬂammation is associated with risk of
developing depression in a dose–response manner; an observa-
tion that would support an argument for causality.
Depression is also known to be more common among women
than men.15 Miller and Raison16 have theorised that this may
partly reﬂect an evolutionary adaptation among women such that
depressive symptoms function as avoidance behaviour with the
effect of minimising infection by external pathogens in reproduc-
tive years.17 Studies have suggested that women react more
strongly than men to stressful stimuli by way of heightened
inﬂammation,18 and are more likely than men to develop
depressive symptoms in response to equal amounts of drug-
induced pro-inﬂammatory cytokines.19 It may therefore be
expected that women are most affected by repeated exposure
to systemic inﬂammation by way of greater depression risk;
studies examining this are scarce.
We examined whether repeated exposure to systemic inﬂam-
mation increases the risk of developing new depressive symptoms
by analysing repeated measures of CRP from a population-based
sample of older adults.
MATERIALS AND METHODS
Study population
Data were drawn from the English Longitudinal Study of Ageing (ELSA), a
nationally representative panel study of community-dwelling adults aged
50 years and older in England.20 Questionnaire data have been collected
every 2 years since 2002/03 and biological data have been collected every
4 years since 2004/05. Participants gave informed written consent to
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participate and ethical approval was obtained from the London Multi-
centre Research Ethics Committee.
Assessment of systemic inﬂammation
High-sensitivity CRP was used as a blood-based marker of systemic
inﬂammation, measured in serum using the N Latex high-sensitivity CRP
mono immunoassay on the Behring Nephelometer II analyser with a
0.17 mg l− 1 detection limit and a coefﬁcient of variation o6%.21
Measurements of CRP from two occasions (2004/05 and 2008/09) were
used for this study. Participants were considered to be inﬂamed on each
occasion if their CRP was 3 mg l− 1 or higher based on recommendations
for cardiovascular outcomes.22 We note that an equivalent cut-point is not
available for mental health outcomes and that 3 mg l− 1 corresponds
approximately to the upper tertile of CRP values in our sample.
Assessment of depressive symptoms
Depressive symptoms were assessed in a consistent manner on three
occasions, once in 2004/05, once in 2008/09 and once in 2012/13 using
symptoms identiﬁed through the Centre for Epidemiologic Studies
Depression (CES-D short version) eight-item scale, which has been well
validated in samples of older adults.23–25 Items referred to experiences in
the past week and included feelings of depression, sadness, loneliness, a
lack of enjoyment, a lack of happiness, that everything was an effort, that
they ‘could not get going’ and that their sleep was restless. The CES-D
score represented the total number of depressive symptoms (out of 8) that
a participant reported having. Scoring positive for at least four of the eight
symptoms questioned in the short version CES-D is often considered to
represent a threshold for the binary presence of depressive
symptomology,26–28 which is similar to the threshold of 16 used in the
longer version CES-D20.
Assessment of covariates
Data on measured covariates were used from 2008/09 to coincide with the
main study baseline. At both time points, demographic factors included
participant age, sex and wealth. Wealth summarised participants’
accumulated resources based not on pension income but on the debt-
free value of major assets (that is, housing, investments and goods).20
Measured height (in metres, m) and weight (in kilograms, kg) were used to
calculate body mass index (BMI, in kg/m2). Chronic disease burden was
examined through self-reported physician diagnosis of a range of diseases
that are common at older ages including cardiovascular disease
(myocardial infarction, angina or stroke), type 2 diabetes, cancer,
osteoarthritis, rheumatoid arthritis, chronic lung disease and asthma.
Disability was assessed using 14 items on basic and instrumental activities
of daily living that cover daily tasks required for independent functioning
including the ability to prepare food, to bathe and to make telephone calls;
participants were considered disabled if they reported ⩾ 1 such limitation.
Cognitive impairment was indicated by poor performance on two
cognitive tests, ﬁrst being a memory test based on the total number of
words recalled immediately and after a delay from a list of 10 words (each
presented 2 s apart), and the second being an executive function test
based on the total number of exemplars of a given category (animals)
named in 1 min. Such measures have been validated against clinical
assessments of neuropathology during autopsy29 and extensively used in
ELSA30–32 and other epidemiological studies. For present analyses, scores
on each test were standardised and summed, and participants scoring 1 s.
d. below the sample mean on this summed score were considered
cognitively impaired. Participants’ smoking status was categorised as
never-smoker, former smoker or current smoker. Participants’ self-reported
frequency of physical activity was divided into three groups based on
doing moderate or vigorous activities: (1) more than once/week, (2) once/
week or (3) one to three times/month, hardly ever or never. Use of
antidepressant medication was identiﬁed through British National
Formulary codes for tricyclic antidepressants (4.3.1), selective serotonin
reuptake inhibitor antidepressants (4.3.3) and other antidepressants (4.3.4),
as recorded by a nurse in 2012/13.
Statistical approach
All analyses were conducted on participants who were free of depressive
symptoms (had less than four of eight symptoms) in both 2004/05 and
2008/09 (Figure 1).
We ﬁrst examined the number of occasions with high CRP (1 vs 0, and 2
vs 0) in relation to continuous change in the number of depressive
Figure 1. Outline of the prospective study design for developing depressive symptoms using the English Longitudinal Study of Ageing. BMI,
body mass index; CES-D, Centre for Epidemiologic Studies Depression; CRP, C-reactive protein.
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symptoms from the main study baseline until the end of follow-up by
subtracting the 2008/09 symptom score value from the 2012/13 symptom
score value, using linear regression. The ﬁrst model adjusted for age, sex
and wealth. Adjustments were made for measured covariates in a series of
additional models: the second included antidepressant drug use in
2012/13 (coinciding with follow-up depressive symptom assessment); the
third included BMI, each individual chronic disease, disability and cognitive
impairment; the fourth included smoking and physical activity; and the
ﬁfth included all factors collectively.
Logistic regression models were then used to compare the odds of
having depressive symptoms (more than or equal to four of eight
symptoms) in 2012/13 according to the number of occasions (1 vs 0, and 2
vs 0) with high CRP, measured in 2004/05 and 2008/09 (the two occasions
that preceded the follow-up assessment of depressive symptoms).
Analyses were repeated on a subset of participants who were free of all
eight depressive symptoms in 2004/05 and 2008/09 in order to compare
the odds of developing each individual symptom in 2012/13 according to
the number of occasions inﬂamed.
For each analysis, an interaction was tested between participant sex and
the exposure (number of occasions inﬂamed) in relation to the outcome
(continuous change in the number of depressive symptoms or binary
development of depressive symptomology), adjusting for age, sex and
wealth.
Sensitivity analyses
Given the possibility that very high values of CRP may represent an occult
inﬂammatory disorder, analyses of repeated inﬂammation in relation to
continuous change in the number of depressive symptoms and binary
development of depressive symptomology were repeated on a subset of
participants who had CRP values o10 mg l− 1 on each occasion, as
recommended for cardiovascular disease prevention,22 again due to lack of
a recognised cut-point for depressive outcomes.
All analyses were performed using SPSS version 24 (SPSS, Chigaco, IL,
USA), with two-tailed Po0.05 guiding statistical signiﬁcance.
RESULTS
Included and excluded study populations
A total of 2068 participants were free of depressive symptoms
(less than four of eight symptoms) in 2004/05 and 2008/09 and
also had data on CRP on those same occasions, had follow-up data
on depression status in 2012/13, and had data on covariates in
2008/09. Compared with participants who did not have depressive
symptoms on these two baseline occasions but were excluded
from the analytic sample (maximum n= 2667), those included did
not differ by sex (P= 0.89) but were younger (67.3 vs 70.0 years,
Po0.001) and less likely to be in the lowest wealth quintile (12.5%
vs 17.8%, Po0.001). Participants included in the sample had a
slightly lower BMI (27.9 vs 28.3 kg/m2, P= 0.02), a lower chronic
disease burden in terms of type 2 diabetes (1.1% vs 2.1%, P= 0.01),
cardiovascular disease (2.0% vs 3.6%, P= 0.001), cancer (3.6% vs
6.2%, Po0.001) and rheumatoid arthritis (5.2% vs 6.8%, P= 0.02),
and were less likely to be disabled (18.1% vs 29.4%, Po0.001).
Included participants had a lower prevalence of low physical
activity (13.2% vs 26.1%, Po0.001) but had a similar smoking
prevalence (9.3% vs 11.0%, P= 0.07), and were less likely to use
antidepressant medication in 2012/13 (6.6% vs 9.5%, P= 0.002).
Included participants were less likely to be inﬂamed on one
occasion (22.3% vs 26.6%, P= 0.001) but were more likely to be
inﬂamed on two occasions (19.7% vs 7.3%, Po0.001). The
proportion of participants who reported in 2003/04, before
completing the baseline assessment, having ever been previously
diagnosed with depression by a physician was similar between
those included and excluded from the analytic sample (4.7% vs
3.7%, respectively, P= 0.08).
Participant characteristics
Characteristics at baseline are shown in Table 1 for those
participants who were initially without depressive symptoms in
2004/05 and 2008/09. Of these 2068 participants, 1200 were not
inﬂamed on either of two baseline occasions while 461 were
inﬂamed on one occasion and 407 were inﬂamed on two
occasions. Participants inﬂamed on two occasions were most
likely to be within the lowest wealth quintile (17.2% vs 9.6% for
zero occasion, Po0.001), had the highest mean BMI (31.1 vs
26.7 kg/m2 for zero occasion, Po0.001), had the highest rate of
current smoking (14.3% vs 7.7% for zero occasions, Po0.001) and
had the highest rate of low physical activity (20.4% vs 9.3%,
Po0.001). Participants inﬂamed on two occasions were also most
likely to be disabled (25.8% vs 14.7% for zero occasions, Po0.001)
and had the highest frequency of chronic diseases except for type
2 diabetes, cardiovascular disease and cancer. The distribution of
CRP at each measurement occasion was positively skewed with a
median (range) of 1.70 (0.20, 210.0) in 2004/05 and of 1.80 (0.20,
126.0) in 2008/09.
Table 1. Baseline characteristics of adults without depression according to the number of occasions inﬂamed over the observation period (n= 2068)
Inﬂamed on zero occasions
(n= 1200)
Inﬂamed on one occasion
(n= 461)
Inﬂamed on two occasions
(n=407)
Baseline characteristics (2008/09)
Age—mean (s.d.) 66.7 (7.6) 68.6 (8.3)a 67.5 (7.9)
Female 612 (51.0) 236 (51.2) 242 (59.5)a
Lowest wealth quintile 115 (9.6) 73 (15.8)a 70 (17.2)a
Uses antidepressant medication 68 (5.7) 28 (6.1) 41 (10.1)a
Body mass index—mean (s.d.) 26.7 (3.9) 28.5 (4.6)a 31.1 (5.7)a
Reported type 2 diabetes 14 (1.2) 4 (0.9) 5 (1.2)
Reported cardiovascular disease 19 (1.6) 15 (3.3)a 7 (1.7)
Reported cancer 38 (3.2) 23 (5.0) 14 (3.4)
Reported osteoarthritis 270 (22.5) 110 (23.9) 118 (29.0)a
Reported rheumatoid arthritis 52 (4.3) 21 (4.6) 34 (8.4)a
Reported chronic lung disease 27 (2.3) 18 (3.9) 26 (6.4)a
Reported asthma 94 (7.8) 54 (11.7)a 58 (14.3)a
Disabled based on activity limitations 176 (14.7) 93 (20.2)a 105 (25.8)a
Cognitively impaired 135 (11.3) 78 (16.9)a 72 (17.7)a
Currently smokes 92 (7.7) 43 (9.3) 58 (14.3)a
Low physical activity 111 (9.3) 79 (17.1)a 83 (20.4)a
New depressive symptoms after 4 yearsb 62 (5.2) 27 (5.9) 42 (10.3)a
Data are n (%) unless otherwise noted. aIndicates signiﬁcantly different from the ‘inﬂamed on zero occasions’ group (Po0.05) based on linear or logistic
regression. bMeasured at follow-up (2012/13).
Repeated exposure to systemic inﬂammation
JA Bell et al
3
Translational Psychiatry (2017), 1 – 8
Number of occasions with systemic inﬂammation and change in
the number of depressive symptoms
We ﬁrst examined the number of occasions inﬂamed in relation to
continuous change in the number of depressive symptoms.
Change scores for the number of depressive symptoms from
2008/09 to 2012/13 were normally distributed around 0 with a
small positive tendency (mean= 0.30, s.d. = 1.42). In models
adjusted for age, sex and wealth, 1 vs 0 occasion of inﬂammation
was not associated with a mean increase in depressive symptoms
(−0.05, 95% conﬁdence intervals (CIs) =− 0.21, 0.10, symptoms),
while 2 vs 0 occasions of inﬂammation were associated with a
small increase (0.19, 95% CI = 0.03, 0.35 symptoms). This increase
was modest without statistical signiﬁcance after adjusting for all
measured covariates (0.10, 95% CI =− 0.07, 0.28 symptoms). No
strong evidence was observed for an interaction between the
number of occasions inﬂamed and participant sex in relation to
continuous change in the number of depressive symptoms
(P= 0.18).
Number of occasions with systemic inﬂammation and odds of
developing depressive symptomology
One hundred and thirty-one new cases of depressive symptomol-
ogy (more than or equal to four of eight symptoms) were
observed in 2012/13. The crude rate of developing depressive
symptoms was similar among adults inﬂamed on 1 vs 0 occasions
(5.9% vs 5.2%, P= 0.58) but increased among those inﬂamed on 2
vs 0 occasions (10.3% vs 5.2%, Po0.001); Table 1). Adjusting for
age, sex and wealth (Table 2), adults who were inﬂamed on 1 vs 0
occasion showed no higher odds of developing depressive
symptoms, while those inﬂamed on 2 vs 0 occasions showed
1.85 (95% CI = 1.22, 2.80) times higher odds. Excess risk among
those inﬂamed on two occasions remained elevated after
alternative adjustments for health and behavioural covariates
and for all measured covariates (odds ratio (OR) = 1.60, 95%
CI = 1.00, 2.55 vs 0 occasions, P= 0.05).
Some evidence for an interaction was found between the
number of occasions inﬂamed and participant sex in relation to
odds of developing depressive symptoms (P-interaction = 0.035).
In sex-stratiﬁed analyses adjusting for age and wealth (Table 3),
men who were inﬂamed on 2 vs 0 occasions did not have
increased odds of developing depressive symptoms (OR= 0.98,
95% CI = 0.45, 2.15), while women who were inﬂamed on 2 vs 0
occasions showed markedly increased odds (OR = 2.61, 95%
CI = 1.56, 4.39); these remained elevated after adjustment for all
measured covariates (OR= 2.75, 95% CI = 1.53, 4.95).
Number of occasions with systemic inﬂammation and odds of
developing individual depressive symptoms
When examining the number of occasions inﬂamed in relation to
odds of developing each depressive symptom in 2012/13 among
a subset of participants initially free of all symptoms in both
2004/05 and 2008/09 (n= 813, Figure 2), associations were
observed only for 2 vs 0 occasions of inﬂammation with one
‘somatic’ depressive symptom, feeling that everything was an
effort (OR = 3.73, 95% CI = 1.66, 8.35 vs 0 occasions) and three
‘psychological’ depressive symptoms, unhappiness (OR= 3.22,
95% CI = 1.41, 7.36 vs 0 occasions), loneliness (OR = 6.33, 95%
CI = 2.18, 18.35 vs 0 occasions) and lack of enjoyment (OR= 4.67,
95% CI = 1.90, 11.52 vs 0 occasions). Evidence was weaker for an
association of 2 vs 0 occasions of inﬂammation with symptoms of
sadness (OR= 1.63, 95% CI = 0.85, 3.14), restless sleep (OR= 1.57,
95% CI = 0.92, 2.70), difﬁculty getting going (OR= 1.89, 0.81, 4.37);
evidence was weakest for the symptom of depression (OR= 1.12,
95% CI = 0.40, 3.13).
Sensitivity analyses
To examine whether excluding participants with acute inﬂamma-
tion modiﬁed our results, we further excluded participants with a
CRP value ⩾ 10 mg l− 1. Similar to previous results, increased risk of
developing depressive symptoms was observed among those
with 2 vs 0 occasions of inﬂammation (OR= 1.73, 95% CI = 1.04,
2.90 with adjustment for all measured covariates; Supplementary
Appendix 1). In sex-stratiﬁed analyses (Supplementary Appendix
2), 2 vs 0 occasions of inﬂammation were associated with 3.41
(95% CI = 1.81, 6.40) times higher odds of developing depressive
symptoms among women. This association was not observed
in men.
DISCUSSION
This study aimed to determine whether repeated exposure to
systemic inﬂammation increases the risk of developing new
depressive symptoms. Within a population-based sample of older
adults who were initially free of depressive symptoms based on
having fewer than four of eight symptoms on two prior occasions,
our results suggested that being inﬂamed on both of vs neither of
Table 2. Odds of developing depressive symptoms after 4 years among adults initially without depressive symptoms, based on the number of
occasions inﬂamed (n= 2068)
Odds of developing depressive symptoms after 4 years
Model 1 (age,
sex and wealth)
Model 1+antidepressant
drug usea
Model 1+BMI, chronic diseaseb,
disability and cognitive impairment
Model 1+smoking
and physical activity
Adjusted for
all factors
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Inﬂammatory status
Inﬂamed on zero
occasions (n= 1200)
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Inﬂamed on one
occasion (n= 461)
1.03 (0.64, 1.65) 1.03 (0.64, 1.65) 0.98 (0.61, 1.60) 0.98 (0.61, 1.58) 0.96 (0.59, 1.56)
Inﬂamed on two
occasions (n= 407)
1.85 (1.22, 2.80) 1.78 (1.17, 2.71) 1.74 (1.10, 2.75) 1.68 (1.10, 2.57) 1.60 (1.00, 2.55)
Abbreviations: CI, conﬁdence interval; CRP, C-reactive protein. The number of occasions inﬂamed considers having CRP ⩾ 3 mg l−1 at either none of, one of or
both of 2004/05 and 2008/09. Outcome deﬁned as having depressive symptoms (more than or equal to four of eight symptoms) vs not having depressive
symptoms (less than four of eight symptoms) in 2012/13. Covariates are assessed in 2008/09. aAntidepressant drug use based on nurse-coded drugs in
2012/13. bChronic disease considers prevalent/recent cardiovascular disease (myocardial infarction, angina or stroke), type 2 diabetes, cancer, osteoarthritis,
rheumatoid arthritis, chronic lung disease and asthma.
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these same occasions conferred an increased risk of future
depressive symptomology. The same ﬁnding was observed
whether analysing depressive symptoms as continuous change
or considering positive cases as having at least four of eight
symptoms. This association appeared to be sex-speciﬁc such that
repeated inﬂammation was associated with increased risk among
women, but not among men. Findings of sex-interaction were
sensitive to the modelling strategy suggesting that associations
either reﬂect subgroup differences or artefacts of inherent biases.
We ﬁrst examined worsened depressive symptom status by
relating continuous change in the number of depressive
symptoms to the number of occasions inﬂamed, among
participants initially free of depressive symptomology; these
results suggested an association for repeated inﬂammation that
was small in magnitude, possibly reﬂecting the rarity of change in
depressive symptoms in this non-clinical sample or non-linear
outcome associations. We then examined worsened symptom
status through the likelihood of having at least four of eight
depressive symptoms as done previously.26–28 These results
suggested that multiple occasions of inﬂammation increased risk
of future depressive symptoms among women only, an associa-
tion that was robust to adjustment for a range of social, health and
behavioural factors and which persisted after excluding women
with very high CRP levels, together suggesting that excess risk did
not generally reﬂect a higher burden of chronic disease or occult
infection. Our results agree with one recent study, which reported
that high levels of IL-6 measured on two separate occasions had
greater predictive power for future depressive symptoms than
high IL-6 measured on a single occasion,33 suggesting that
inﬂammation confers greater risk of new depressive symptoms
when exposure persists over time. CRP is a relatively large protein
thought to be less responsive to minor ﬂuctuations in health than
small cytokines such as IL-6,34 and repeated measures of CRP may
therefore be useful for indicating long-term exposure to
inﬂammation; this has not been previously examined.
Furthermore, given that somatic symptoms of depression may
reﬂect adaptive energy-conserving responses to inﬂammation17
these symptoms may be expected to develop most readily in
response to repeated inﬂammation; a theory supported by recent
cross-sectional results showing only depressive symptoms of a
somatic nature to be associated with raised CRP.35 This symptom
pattern was not clearly observed in the present study, with
repeated inﬂammation predicting development of three symp-
toms that may be deemed psychological or affective (unhappi-
ness, loneliness and lack of enjoyment) and only one symptom
that may be deemed somatic (feeling everything was an effort);
this may however reﬂect low statistical power, given positive
effect sizes for other somatic symptoms with trends towards
signiﬁcance. The older age of participants in this study may have
also inﬂuenced the type of symptoms that were associated with
inﬂammation, given that these may be conditioned by declining
physical health, multi-morbidity and loss of social networks;36
symptoms may differ from those arising in earlier life stages. Data
on early life symptoms were not available and so it was not
possible to examine this issue or indeed determine whether
symptoms observed here were truly new or a recurrence of
previous symptomology.
Systemic inﬂammation may exert depressogenic effects
through several mechanisms including disrupting the metabolism
of the neurotransmitters serotonin and dopamine,37 impairing
reward sensitivity in the basal ganglia and threat sensitivity in the
anterior cingulate cortex,5 hyper-activation of the hypothalamic–
pituitary–adrenal axis,6,38 and inducing glucocorticoid resistance.4
Such pathways may be triggered by persistent inﬂammation, but
it is not yet clear why such mechanisms would have stronger
effects on mood states among women. Most of the previous
studies that reported associations between peripheral inﬂamma-
tion and new depressive symptoms did not examine sex
differences, and the one study that did so did not ﬁnd strong
evidence for differential associations between inﬂammation and
depression among men and women.8 None of the previous
studies which found no effect of inﬂammation on future
depressive symptoms seemed to examine sex differences.12–14
Twice as many new cases of depressive symptoms were observed
Table 3. Odds of developing depressive symptoms after 4 years among men and women initially without depressive symptoms, based on the
number of occasions inﬂamed (n= 2068)
Odds of developing depressive symptoms after 4 years
Model 1
(age and wealth)
Model 1+antidepressant
drug usea
Model 1+BMI, chronic diseaseb,
disability and cognitive impairment
Model 1+smoking
and physical activity
Adjusted for
all factors
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Among men
Inﬂamed on zero
occasions (n= 588)
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Inﬂamed on one
occasion (n= 225)
0.44 (0.18, 1.08) 0.44 (0.18, 1.09) 0.40 (0.16, 1.02) 0.40 (0.16, 1.00) 0.38 (0.15, 0.98)
Inﬂamed on two
occasions (n= 165)
0.98 (0.45, 2.15) 0.96 (0.44, 2.12) 0.79 (0.34, 1.82) 0.83 (0.36, 1.87) 0.70 (0.29, 1.68)
Among women
Inﬂamed on zero
occasions (n= 612)
1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Inﬂamed on one
occasion (n= 236)
1.63 (0.91, 2.90) 1.62 (0.91, 2.89) 1.66 (0.91, 3.01) 1.62 (0.90, 2.92) 1.67 (0.91, 3.06)
Inﬂamed on two
occasions (n= 242)
2.61 (1.56, 4.39) 2.51 (1.49, 4.22) 2.83 (1.58, 5.04) 2.55 (1.50, 4.32) 2.75 (1.53, 4.95)
Abbreviations: CI, conﬁdence interval; CRP, C-reactive protein. The number of occasions inﬂamed considers having CRP ⩾ 3 mg l−1 at either none of, one of or
both of 2004/05 and 2008/09. Outcome deﬁned as having depressive symptoms (more than or equal to four of eight symptoms) vs not having depressive
symptoms (less than four of eight symptoms) in 2012/13. Covariates are assessed in 2008/09. aAntidepressant drug use based on nurse-coded drugs in
2012/13. bChronic disease considers prevalent/recent cardiovascular disease (myocardial infarction, angina or stroke), type 2 diabetes, cancer, osteoarthritis,
rheumatoid arthritis, chronic lung disease and asthma.
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among women than men in the present study, which could reﬂect
genuine sex differences in inﬂammatory reactivity to stressful
stimuli,15 in depressive effects of inﬂammatory cytokines,19 or in
wider adaptations related to pathogen–host defence.17 One
recent study found higher total white blood cell count to predict
an increase in depressive symptoms over time among women
only39 providing further evidence for sex-speciﬁcity; risk was not
examined in relation to persistency of inﬂammation. Alternatively,
differential associations by sex may reﬂect methodological issues,
such as inferior measurement of depressive symptoms among
men, artefacts of selection bias or statistical false positives.
Mood-altering effects of inﬂammation have some support from
trial evidence on clinical populations, which suggests that
administration of the pro-inﬂammatory cytokine interferon-alpha
induces depressive symptoms among previously non-depressed
adults,40 and that administration of an anti-inﬂammatory TNF-α
antagonist reduces depressive symptoms in patients with high
CRP levels.41 However, a recent population-based study using
Mendelian randomisation analyses found no evidence of associa-
tion between genetically elevated CRP and depressive
symptoms,42 indicating that circulating CRP itself may not be a
causal factor within the wider population. As a marker of
inﬂammation measured in the periphery, high CRP may reﬂect
activity of more upstream pro-inﬂammatory factors, such as IL-6
and IL-1B which may themselves induce changes in brain function
predisposing to depression.4,43
Strengths and limitations
Strengths of this study include its use of repeated measures on a
well-validated marker of systemic inﬂammation in order to
examine the issue of persistent versus transient exposure, a
population-based sample, and a prospective design with 4 years
of follow-up. We used a self-reported symptom scale to deﬁne
depression-related phenomena that allows not for a clinical
diagnosis but an assessment of subjective mood. Study limitations
include its observational design that limits causal inference, given
the possibility of residual confounding and reverse causation bias.
Data were absent on use of anti-inﬂammatory or related
prescription drugs at baseline that may have affected levels of
systemic inﬂammation; rates of prescription drug use are however
expected to be high throughout this population, given their older
age and are not likely speciﬁc to those who are systemically
inﬂamed. Alcohol consumption was not included as a covariate
due to the volume consumed not being measured and due to a
large degree of missing data on other aspects of consumption,
which would have further reduced the precision of results.
Consumption of alcohol and a range of food groups have been
associated positively with systemic inﬂammation44 and may
subsequently lead to depressive symptoms, but high alcohol
consumption is also known to cluster with other health
behaviours including smoking and low physical activity,45 both
of which were considered here. Participants were of an older age
when exclusion of those with depressive symptoms at baseline
were made, which may have missed severe cases or symptoms
that developed earlier in life. Participants analysed were also
relatively healthy compared with the source population; this could
result in conservative effect estimates but also in artefacts of
selection bias. The prospective study design restricted the number
of participants available for analyses and resulted in some
imprecision in effect estimates by way of relatively wide
conﬁdence intervals indicating that effect sizes should be
interpreted with caution.
CONCLUSIONS
In this cohort study of older adults, repeated, but not transient,
exposure to systemic inﬂammation was associated with increased
risk of future depressive symptoms among women. This subgroup
ﬁnding requires causal analyses spanning other age groups to
conﬁrm its validity. Intervention studies would ultimately be
needed to determine whether reducing systemic inﬂammation
through use of anti-inﬂammatory drugs or lifestyle interventions
would prevent the onset of depressive symptoms.
CONFLICT OF INTEREST
ETB works half-time for the University of Cambridge and half-time for
GlaxoSmithKline; he holds stock in GSK. The remaining authors declare no conﬂict
of interest.
Figure 2. Odds of developing individual depressive symptoms after 4 years based on the number of occasions inﬂamed (n= 813). Symptoms
refer to experiences in the week preceding assessment. Sample includes 497 participants inﬂamed on zero occasions, 178 participants
inﬂamed on one occasion and 138 participants inﬂamed on two occasions.
Repeated exposure to systemic inﬂammation
JA Bell et al
6
Translational Psychiatry (2017), 1 – 8
ACKNOWLEDGMENTS
Data for the English Longitudinal Study of Ageing (ELSA) were accessed through the
UK Data Archive. ELSA was developed by a team of researchers based at University
College London, the Institute of Fiscal Studies, the University of Manchester and
NatCen Social Research. Funding was provided by the National Institute on Aging in
the United States (RO1AG7644) and a consortium of UK government departments
coordinated by the Economic and Social Research Council. LAC is supported by the
British Heart Foundation and the MRC ImmunoPsychiatry Consortium (RG71546). MK
is supported by the Medical Research Council (MR/K013351/1), NordForsk, the Nordic
Programme on Health and Welfare, and an Economic and Social Research Council
professorial fellowship (ES/J023299/1). AS is supported by the British Heart
Foundation. The funders had no role in the study design; in the collection, analysis
and interpretation of data; in writing of the report; or in the decision to submit the
paper for publication. The developers and funders of the English Longitudinal Study
of Ageing do not bear any responsibility for the analyses or interpretations
presented here.
AUTHOR CONTRIBUTIONS
JAB had full access to the data and takes primary responsibility for
the integrity and accuracy of results. LAC obtained funding,
supervised, contributed to the concept and design of study,
drafting and all authors contributed to the critical revision of
the manuscript.
LIST OF CONSORTIUM MEMBERS
University of Cambridge, Edward Bullmore (etb23@medschl.cam.
ac.uk), Petra E. Vértes (pv226@cam.ac.uk), Rudolf Cardinal
(rnc1001@cam.ac.uk), Department of Psychiatry, Behavioural and
Clinical Neuroscience Institute, University of Cambridge,
Cambridge CB2 0SZ, MRC Biostatistics Unit (Cambridge), Sylvia
Richardson (sylvia.richardson@mrc-bsu.cam.ac.uk), Gwenael Leday
(gwenael@mrc-bsu.cam.ac.uk), MRC Biostatistics Unit, Cambridge
Institute of Public Health, Forvie Site, Robinson Way, Cambridge
Biomedical Campus, Cambridge CB2 0SR, University of Edinburgh,
Tom Freeman (tfreeman@roslin.ed.ac.uk), David Hume (david.
hume@roslin.ed.ac.uk), Tim Regan (Tim.Regan@roslin.ed.ac.uk),
Zhaozong Wu (Zhaozong.Wu@roslin.ed.ac.uk), System Immunol-
ogy Group, Division of Genetics and Genomics, The Roslin Institute
and Royal (Dick) School of Veterinary Studies, University of
Edinburgh, Easter Bush, Midlothian EH25 9RG, King’s College
London, Carmine Pariante (carmine.pariante@kcl.ac.uk), Anna-
maria Cattaneo (annamaria.cattaneo@kcl.ac.uk), Patricia Zuszain
(patricia.zunszain@kcl.ac.uk), Alessandra Borsini (alessandra.borsi-
ni@kcl.ac.uk), Psychiatry and Immunology Lab & Perinatal
Psychiatry, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London G.32.01, The Maurice Wohl Clinical
Neuroscience Institute, Cutcombe Road, London SE5 8AF, Robert
Stewart (robert.stewart@kcl.ac.uk), David Chandran (david.chan-
dran@kcl.ac.uk), Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, The Maurice Wohl Clinical
Neuroscience Institute, Cutcombe Road, London SE5 9RT, Queen
Mary University (previously at University College London), Livia A.
Carvalho (l.carvalho@qmul.ac.uk), Joshua A. Bell (joshua.bell.11@
ucl.ac.uk), Luis Henrique Souza-Teodoro (l.teodoro@qmul.ac.uk),
Translational Pharmacology & Therapeutic Innovation | William
Harvey Research Institute | Queen Mary University of London |
John Vane Science Centre Charterhouse Square EC1M 6BQ,
University of Southampton, Hugh Perry (V.H.Perry@soton.ac.uk),
Centre for Biological Sciences, University of Southampton, Mail
Point 840 LD80B, South Lab and Path Block, Southampton General
Hospital, SO16 6YD, University of Sussex, Neil Harrison (N.
Harrison@bsms.ac.uk), Brighton & Sussex Medical School, Uni-
versity of Sussex, Brighton BN1 9RR, United Kingdom, Janssen,
Wayne Drevets (wdrevets@ITS.JNJ.com), Janssen Pharmaceuticals
of Johnson and Johnson, Janssen Research & Development, 1125
Trenton-Harbourton Road, Titusville, NJ 08560, Gayle M Wittenberg
(GWittenb@ITS.JNJ.com), Yu Sun (YSun25@its.jnj.com), Janssen
Research & Development, 1125 Trenton-Harbourton Road,
Titusville, NJ 08560, Declan Jones (djone119@ITS.JNJ.com), J&J
Innovation Centre, One Chapel Place London W1G 0BG, Glax-
oSmithKline, Edward Bullmore (Edward.t.bullmore@gsk.com), GSK
Clinical Unit in Cambridge Building, Addenbrookes Hospital, Hills
Road, Cambridge CB2 2GG, Shahid Khan (shahid.a.khan@gsk.com),
Annie Stylianou (anastasia.2.Stylianou@gsk.com), Robert B
Henderson (Robbie.b.henderson@gsk.com), GSK, 1 Gunnelswood
Road, Stevenage SG1 2NY.
REFERENCES
1 Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al. Global
burden of disease attributable to mental and substance use disorders: ﬁndings
from the Global Burden of Disease Study 2010. Lancet 2013; 382: 1575–1586.
2 Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ et al. Burden
of depressive disorders by country, sex, age, and year: ﬁndings from the global
burden of disease study 2010. PLoS Med 2013; 10: e1001547.
3 Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-
analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein
in patients with major depressive disorder. Brain Behav Immun 2015; 49: 206–215.
4 Gold P. The organization of the stress system and its dysregulation in depressive
illness. Mol Psychiatry 2015; 20: 32–47.
5 Nusslock R, Miller GE. Early-life adversity and physical and emotional health across
the lifespan: a neuroimmune network hypothesis. Biol Psychiatry 2016; 80: 23–32.
6 Carvalho L, Bergink V, Sumaski L, Wijkhuijs J, Hoogendijk W, Birkenhager T et al.
Inﬂammatory activation is associated with a reduced glucocorticoid receptor
alpha/beta expression ratio in monocytes of inpatients with melancholic major
depressive disorder. Transl Psychiatry 2014; 4: e344.
7 Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review
and meta-analysis of longitudinal studies. J Affect Disord 2013; 150: 736–744.
8 Gimeno D, Kivimäki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A et al.
Associations of C-reactive protein and interleukin-6 with cognitive symptoms of
depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009; 39:
413–423.
9 Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA et al.
Association of high-sensitivity C-reactive protein with de novo major depression.
Br J Psychiatry 2010; 197: 372–377.
10 Khandaker GM, Pearson RM, Zammit S, Lewis G, Jones PB. Association of serum
interleukin 6 and C-reactive protein in childhood with depression and psychosis
in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014;
71: 1121–1128.
11 Zalli A, Jovanova O, Hoogendijk W, Tiemeier H, Carvalho L. Low-grade inﬂam-
mation predicts persistence of depressive symptoms. Psychopharmacology 2015;
1–10.
12 Chocano-Bedoya PO, Mirzaei F, O’Reilly EJ, Lucas M, Okereke OI, Hu FB et al. C-
reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and
incident clinical depression. J Affect Disord 2014; 163: 25–32.
13 Stewart JC, Rand KL, Muldoon MF, Kamarck TW. A prospective evaluation of the
directionality of the depression–inﬂammation relationship. Brain Behav Immun
2009; 23: 936–944.
14 Matthews KA, Schott LL, Bromberger JT, Cyranowski JM, Everson-Rose SA, Sowers
M. Are there bi-directional associations between depressive symptoms and
C-reactive protein in mid-life women? Brain Behav Immun 2010; 24: 96–101.
15 Piccinelli M, Wilkinson G. Gender differences in depression critical review. Br J
Psychiatry 2000; 177: 486–492.
16 Miller AH, Raison CL. The role of inﬂammation in depression: from evolutionary
imperative to modern treatment target. Nat Rev Immunol 2016; 16: 22–34.
17 Raison C, Miller A. The evolutionary signiﬁcance of depression in Pathogen Host
Defense (PATHOS-D). Mol Psychiatry 2013; 18: 15–37.
18 Endrighi R, Hamer M, Steptoe A. Post-menopausal women exhibit greater
interleukin-6 responses to mental stress than older men. Ann Behav Med 2016; 50:
564–571.
19 Udina M, Castellví P, Moreno-España J, Navinés R, Valdés M, Forns X et al.
Interferon-induced depression in chronic hepatitis C: a systematic review and
meta-analysis. J Clin Psychiatry 2012; 73: 1128–1138.
20 Taylor R, Conway L, Calderwood L, Lessof C, Cheshire H, Cox K et al. Health, wealth
and lifestyles of the older population in England: The 2002 English Longitudinal
Study of Ageing Technical Report. National Centre for Social Research, 2007.
Available at: http://www.elsa-project.ac.uk/reportWave1.
21 Graig R, Deverill C, Pickering K. Quality Control of Blood Saliva and Urine Analytes.
The Information Centre: London, 2006.
22 Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M et al.
Markers of inﬂammation and cardiovascular disease application to clinical and
Repeated exposure to systemic inﬂammation
JA Bell et al
7
Translational Psychiatry (2017), 1 – 8
public health practice: a statement for healthcare professionals from the centers
for disease control and prevention and the American Heart Association. Circula-
tion 2003; 107: 499–511.
23 Irwin M, Artin KH, Oxman MN. Screening for depression in the older adult: cri-
terion validity of the 10-item Center for Epidemiological Studies Depression Scale
(CES-D). Arch Intern Med 1999; 159: 1701.
24 Lyness JM, Noel TK, Cox C, King DA, Conwell Y, Caine ED. Screening for depression
in elderly primary care patients: a comparison of the Center for Epidemiologic
Studies--Depression Scale and the Geriatric Depression Scale. Arch Intern Med
1997; 157: 449.
25 Karim J, Weisz R, Bibi Z, ur Rehman S. Validation of the Eight-Item Center for
Epidemiologic Studies Depression Scale (CES-D) among older adults. Curr Psychol
2015; 34: 681–692.
26 Stefﬁck DE. Documentation of Affective Functioning Measures in the Health and
Retirement Study. Survey Research Center, University of Michigan: Ann Arbor, MI,
2000.
27 Hamer M, Molloy GJ, de Oliveira C, Demakakos P. Persistent depressive
symptomatology and inﬂammation: to what extent do health behaviours
and weight control mediate this relationship? Brain Behav Immun 2009; 23:
413–418.
28 Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty G. Insulin-like growth
factor 1 and risk of depression in older people: the English Longitudinal Study
of Ageing. Transl Psychiatry 2016; 6: e898.
29 Wilson R, Leurgans S, Boyle P, Schneider J, Bennett D. Neurodegenerative basis of
age-related cognitive decline. Neurology 2010; 75: 1070–1078.
30 Shankar A, Hamer M, McMunn A, Steptoe A. Social isolation and loneliness:
relationships with cognitive function during 4 years of follow-up in the English
Longitudinal Study of Ageing. Psychosom Med 2013; 75: 161–170.
31 Hamer M, Stamatakis E. Prospective study of sedentary behavior, risk of depres-
sion, and cognitive impairment. Med Sci Sports Exerc 2014; 46: 718.
32 Souza-Teodoro LH, de Oliveira C, Walters K, Carvalho LA. Higher serum dehy-
droepiandrosterone sulfate protects against the onset of depression in the
elderly: Findings from the English Longitudinal Study of Aging (ELSA). Psycho-
neuroendocrinology 2016; 64: 40–46.
33 Kivimäki M, Shipley M, Batty GD, Hamer M, Akbaraly T, Kumari M et al. Long-term
inﬂammation increases risk of common mental disorder: a cohort study. Mol
Psychiatry 2014; 19: 149.
34 Ashley NT, Weil ZM, Nelson RJ. Inﬂammation: mechanisms, costs, and natural
variation. Annu Rev Ecol Evolut Syst 2012; 43: 385–406.
35 Jokela M, Virtanen M, Batty GD, Kivimäki M. Inﬂammation and speciﬁc symptoms
of depression. JAMA Psychiatry 2016; 73: 87–88.
36 Alexopoulos GS. Depression in the elderly. Lancet 2005; 365: 1961–1970.
37 Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inﬂammation
to sickness and depression: when the immune system subjugates the brain. Nat
Rev Neurosci 2008; 9: 46–56.
38 Carvalho LA, Juruena MF, Papadopoulos AS, Poon L, Kerwin R, Cleare AJ et al.
Clomipramine in vitro reduces glucocorticoid receptor function in healthy sub-
jects but not in patients with major depression. Neuropsychopharmacology 2008;
33: 3182–3189.
39 Beydoun M, Beydoun H, Dore G, Canas J, Fanelli-Kuczmarski M, Evans M et al.
White blood cell inﬂammatory markers are associated with depressive symptoms
in a longitudinal study of urban adults. Transl Psychiatry 2016; 6: e895.
40 Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-α.
Biol Psychiatry 2004; 56: 819–824.
41 Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A et al. Etanercept and
clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-
controlled randomised phase III trial. Lancet 2006; 367: 29–35.
42 Wium-Andersen MK, Ørsted DD, Nordestgaard BG. Elevated C-reactive protein,
depression, somatic diseases, and all-cause mortality: a mendelian
randomization study. Biol Psychiatry 2014; 76: 249–257.
43 Raison CL, Miller AH. Do cytokines really sing the blues? Cerebrum 2013; 2013: 10.
44 Lucas M, Chocano-Bedoya P, Shulze MB, Mirzaei F, O'Reilly EJ, Okereke OI et al.
Inﬂammatory dietary pattern and risk of depression among women. Brain Behav
Immun 2014; 36: 46–53.
45 Mawditt C, Sacker A, Britton A, Kelly Y, Cable N. The clustering of health-related
behaviours in a British population sample: Testing for cohort differences. Prev Med
2016; 88: 95–107.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Repeated exposure to systemic inﬂammation
JA Bell et al
8
Translational Psychiatry (2017), 1 – 8
